VTVivian Thuyanh Thieu

Vivian Thuyanh Thieu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vivian Thuyanh Thieu has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes

    by Stefano Del Prato, Robert J. Heine, Federico C. Pérez Manghi, Stanley H. Hsia, Elisa Gomez-Valderas, Meltem Zeytinoglu, Elisa Razzoli, Jacek Kiljanski, Palash Sharma, Alastair Knights, et al.

    Initiation of treatment with tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GLP-1RA), early after a diagnosis of type 2 diabetes (T2D) may establish better and more durable glycemic control than current treatment approaches per guidelines and clinical practice. To assess the efficacy and safety of tirzepatide versus intensified conventional care (ICC) in participants with early T2D who have inadequate glycemic control with diet, exercise, and metformin. Randomized, open-label, parallel-group, phase 4 trial (SURPASS-EARLY). (ClinicalTrials.gov: NCT05433584). 78 sites in 10 countries. 794 adults with at most 4 years of T2D history treated with metformin. Tirzepatide (15 mg or maximum tolerated dose) or ICC (including GLP-1RAs but excluding tirzepatide) used in clinical practice and supported by local treatment guidelines. The primary objective was to show the noninferiority of tirzepatide to ICC for change in hemoglobin A1c (HbA1c) from baseline to 2 years. Secondary objectives were to show the superiority of tirzepatide for change in HbA1c, weight, and waist circumference. Tirzepatide was superior to ICC for mean changes from baseline to 2 years in HbA1c (-1.99 percentage points [95% CI, -2.12 to -1.87 percentage points] vs. -1.32 percentage points [CI, -1.44 to -1.19 percentage points]; estimated treatment difference [ETD], -0.68 percentage points [CI, -0.84 to -0.51 percentage points]; P < 0.001), weight (ETD, -8.0 kg [CI, -9.39 to -6.50 kg]; P < 0.001), and waist circumference (ETD, -6.2 cm [CI, -7.54 to -4.93 cm]; P < 0.001) (treatment regimen estimand). More participants achieved normoglycemia (HbA1c 1c, weight, and waist circumference, and more participants achieved normoglycemia (HbA1c <5.7%) with tirzepatide than ICC after 2 years. Eli Lilly and Company.

  • Open Access

    The value and impact of weight reduction from the perspective of people with type 2 diabetes in the United States

    by Melissa M. Ross, Sarah Mulnick, Kristina S. Boye, Ashley Samuelson, Vivian Thuyanh Thieu, Christine Longuet, Jennifer Glass, Meredith M. Hoog

    Aims: To understand the importance and potential impacts of reaching a lower weight or body mass index (BMI) from the perspectives of people with type 2 diabetes (T2D) across BMI levels. Materials and methods: A cross‐sectional survey, informed by qualitative interviews, was administered to a sample representative of the US T2D population by BMI. The survey asked about experience and perceptions of weight management, the impact of T2D on quality of life (QoL), and the value of 5%, 10%, and 20% weight reductions. Results were summarised descriptively. Results: Among 388 participants (54% male; 10% Hispanic; 90% White; mean age 61 years [SD: 13]; mean self‐reported BMI 32.7 kg/m 2 [SD: 8.4]), 47% had a current haemoglobin A1c <7%. T2D affected QoL with impacts on comorbidities (39%), health complications (29%), emotional well‐being (29%), and daily activities (28%). Most reported that the impact of weight on T2D was an issue (89%), they needed to lose weight (87%), and they struggled to lose weight (76%). Nearly all felt weight management was important to managing their T2D (93%), and 5%/10%/20% weight reductions would positively impact their perception of their future with T2D (60%/74%/69%, respectively). The majority felt 5%/10%/20% weight reductions would have positive impacts (72%/79%/70%, respectively), specifically on their appearance (70%/81%/83%, respectively), comorbidities (59%/72%/80%, respectively), and emotional well‐being (51%/58%/66%, respectively). Conclusions: People with T2D, across BMI categories, place considerable value on the opportunity for weight reduction yet endure considerable challenges in doing so through lifestyle interventions, even when weight reduction is discussed with their healthcare provider.


  • Open Access

    Therapeutic Inertia in an Insured Population with Type 2 Diabetes in the United States: A Retrospective Cohort Study

    by Kristina S. Boye, Maureen J. Lage, Kendra A. Terrell, Vivian T. Thieu

    Introduction This study examines the characteristics of adults with type 2 diabetes (T2D) who were not initially treated with an antihyperglycemic agent (AHA). Methods The analyses used Optum de-identified Market Clarity data from January 2013 through September 2023. The US study included nonpregnant adults with T2D who were continuously insured from 1 year prior through 5 years post diagnosis and did not fill a prescription for an AHA in the year after their initial T2D diagnosis. Differences between those treated in years 2–5 with an AHA (delayed treatment) and those untreated with an AHA for 5 years post diagnosis (untreated) were examined descriptively and using multivariable analyses. Results Out of 186,259 adults with T2D, 56.7% (N = 105,533) did not fill a prescription for an AHA in the year after diagnosis and were included in the study. Of these 105,533 adults (mean age 59.6 years; 51.4% female), 75.0% were untreated for the entire 5 years post diagnosis. In the delayed treatment group, metformin was the most common first-line therapy (72.9%), and 83.0% of those who initiated monotherapy never received additional classes of AHAs. Compared to the delayed treatment group, the untreated group had significantly higher rates of incident cardiovascular outcomes and all-cause direct total costs ($118,191 vs $108,687; P < 0.05). Conclusion Over 50% of adults diagnosed with T2D were untreated with an AHA in the first year post diagnosis, and most of those who went untreated the first year remained untreated after 5 years. Among the delayed treatment patients, the majority did not use additional AHA classes besides their index therapy in the post-period. These findings suggest that therapeutic inertia affects a significant percentage of individuals with T2D. Given the untreated group’s significantly worse cardiovascular outcomes and higher medical costs, these findings highlight a potential unmet need in the years immediately following T2D diagnosis.


  • Open Access

    HbA1c reduction with tirzepatide in people with type 2 diabetes: The contribution of weight loss assessed by a mediation analysis

    by Tina Vilsbøll, Maciej T. Malecki, Palash Sharma, Vivian T. Thieu, Krishna Karthik Chivukula, Jacek Kiljanski

    Aim: Tirzepatide is a dual glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) receptor agonist for type 2 diabetes, chronic weight management and obstructive sleep apnoea (in the US). To assess the contribution of weight loss (WL) to the observed glycaemic effect, we performed mediation analysis of three randomized, controlled, parallel, 4‐arm SURPASS(S)‐trials; 1, 2 and 5, for a total of 2831 participants. Materials and Methods: WL dependent (WL‐D) and WL independent (WL‐IND) effects on comparator‐adjusted glycated haemoglobin A1c (HbA1c) reduction at Week 40 were estimated using mediation analysis, adjusted for baseline HbA1c and study‐specific stratification factors. Results: The difference in mean HbA1c change from baseline at 40 weeks (total effect) between tirzepatide and the placebo group ranged from −20.0 to −14.6 mmol/mol, and that between tirzepatide and semaglutide (1 mg) ranged from −5.1 to −1.9 mmol/mol. In the placebo‐controlled trials, 12%–27% of the difference in HbA1c change between tirzepatide dose arms and placebo was estimated as being mediated through WL when given as monotherapy (S1), and 25%–45% when on the background of insulin with or without metformin (S5). Compared with semaglutide, 54%–71% of the difference in HbA1c change between tirzepatide and semaglutide was estimated as being WL‐D. Conclusion: The tirzepatide‐induced HbA1c reductions from baseline, compared with placebo or semaglutide, were mediated through both WL‐D and WL‐IND effects. Estimated contributions of WL to the difference in glycaemic efficacy varied and were highest when tirzepatide was compared with semaglutide and less pronounced when compared with placebo. These results help to understand that other factors beyond weight reduction contribute to HbA1c reduction with tirzepatide.


  • Open Access

    Improvement in body mass index category was associated with improved cardiometabolic measures and patient‐reported outcomes in adults with type 2 diabetes treated with tirzepatide

    by Rodolfo J. Galindo, Clare J. Lee, Sheryl Elaine Allen, Anne Dib, Kristina S. Boye, Vivian Thuyanh Thieu, Wenxiu Dong, Hélène Sapin, Russell J. Wiese

    Aims: To estimate body mass index ( BMI ) category changes after treatment with tirzepatide as well as potential associations between shifting BMI category and selected cardiometabolic measures and weight‐related patient‐reported outcomes ( PROs ) in type 2 diabetes. Materials and Methods: This post‐hoc analysis analysed data from the SURPASS ‐1 to ‐5 trials for weekly tirzepatide (pooled doses) in adults with type 2 diabetes. Changes in BMI category from baseline to Week 40 or 52 (primary endpoint) were assessed and grouped into ‘improved’ (shift to ≥1 lower category) and ‘not improved’ (which included ‘not improved: stable’ [no change in category] or ‘not improved: worsened’ [shift to ≥1 higher category]). BMI categories were 2 , 25 to 2 , 30 to 2 , 35 to 2 , and ≥40 kg/m 2 . Associations of changes in selected cardiometabolic parameters and weight‐related PROs by BMI shift category were also determined. Results: Overall, 58.9% of 3559 participants treated with tirzepatide shifted to an ‘improved’ BMI category, and 41.1% were in the ‘not improved’ BMI category. Participants with an ‘improved’ versus ‘not improved’ BMI category had numerically larger mean improvements from baseline in the majority of the selected cardiometabolic parameters at endpoint in all five SURPASS trials. Improvements in weight‐related PROs were numerically largest for participants whose BMI category ‘improved’. Conclusions: After tirzepatide treatment, approximately 60% of adults with type 2 diabetes shifted to a lower ‘improved’ BMI category. This shift was generally associated with numerical improvements in selected cardiometabolic measures and weight‐related PROs that may reduce cardiometabolic risk.


  • Open Access

    Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme

    by Brandon K. Bergman, Julio Rosenstock, W. Timothy Garvey, Rachel L. Batterham, Yanyun Chen, Minzhi Liu, Palash Sharma, Chrisanthi A. Karanikas, Vivian T. Thieu

    Aims: This participant‐level exploratory analysis assessed the continuous time spent in glycaemic control and/or with sustained weight reductions with tirzepatide treatment in participants with type 2 diabetes (T2D) from the SURPASS programme. Materials and Methods: Participants ( N = 6246) from SURPASS 1–5 were randomized to once weekly tirzepatide (5, 10 or 15 mg) or comparator (once weekly placebo, once weekly semaglutide 1 mg, insulin degludec or insulin glargine). Continuous time spent with HbA1c < 7.0% (53 mmol/mol), ≤6.5% (48 mmol/mol) and ≥5% body weight reduction and combined HbA1c ≤ 6.5% (48 mmol/mol) with a ≥5% body weight reduction were assessed through 40 weeks (SURPASS‐1, ‐2, and ‐5) or 52 weeks (SURPASS‐3 and ‐4). The non‐parametric Wilcoxon rank sum test was used to compare the median duration of continuous time spent in control, and logistic regression was used to analyse the proportion of participants achieving glycaemic control and body weight reduction at any time points or at the end of the primary study period. Results: Median time spent with HbA1c < 7.0% (53 mmol/mol) was 80% (tirzepatide) versus 70% (semaglutide) and 0% (placebo) of the treatment duration in 40‐week studies, and 77%–85% (tirzepatide) versus 62% (insulin degludec) and 23% (insulin glargine) of the treatment duration in 52‐week studies ( p < 0.001). Time spent with HbA1c < 7.0% (53 mmol/mol) was generally similar across all tirzepatide doses in each study. Dose‐dependent increases in time spent with ≥5% body weight reduction were observed with tirzepatide (median time spent: 20%–77% with tirzepatide versus 25% with semaglutide 1 mg) ( p < 0.001). Tirzepatide‐treated participants experienced longer time spent with HbA1c ≤ 6.5% (48 mmol/mol) and ≥5% body weight reduction versus semaglutide (median: 35%–60% vs. 7%) ( p < 0.001). Conclusions: In this post hoc analysis, people with T2D experienced substantially longer continuous time in glycaemic control and more sustained body weight reductions with tirzepatide versus placebo and active comparators.


  • Open Access

    Striving for early effective glycaemic and weight management in type 2 diabetes: A narrative review

    by Alice Y. Y. Cheng, Robert J. Heine, Stefano Del Prato, Jennifer B. Green, Vivian Thuyanh Thieu, Meltem Zeytinoglu

    Despite the recognition by key guidelines that achieving early glycaemic control has important benefits in individuals with type 2 diabetes (T2D) and that addressing excess adiposity is one of the central components of comprehensive person‐centred T2D care, a substantial proportion of individuals with T2D do not meet their metabolic treatment goals. Prior treatment paradigms were limited by important treatment‐associated risks such as hypoglycaemia and body weight gain. Therefore, a more conservative, sequential approach to treatment was typically utilized. One potential consequence of this approach has been a missed opportunity to achieve a ‘legacy effect’, where early treatment to reach glycaemic targets is associated with enduring long‐term benefits in T2D. Additionally, while previous treatment approaches have addressed core defects in T2D, including insulin resistance and β‐cell function decline, they have been unable to address one of the underlying causal abnormalities—excess adiposity. Here, we review currently available evidence for the beneficial long‐term effects of early glycaemic control and management of body weight in people with T2D and discuss potential next steps.


  • Open Access

    An Economic Evaluation of the Relationship Between Glycemic Control and Total Healthcare Costs for Adults with Type 2 Diabetes: Retrospective Cohort Study

    by Kristina S. Boye, Jay P. Bae, Vivian T. Thieu, Maureen J. Lage

    Introduction Glycemic control is associated with better outcomes among individuals with type 2 diabetes (T2D). This research examines total US all-cause medical costs for adults with T2D with recommended glycemic control (HbA1c < 7%) compared to poor glycemic control (HbA1c ≥ 7%). Methods The study used administrative claims data linked to HbA1c laboratory test results from January 1, 2015 through June 30, 2021 to identify adults with T2D with a recorded HbA1c test. Patients with recommended glycemic control at index date were propensity score matched to patients with poor glycemic control. General linear models and two-part models were used to compare all-cause outpatient, drug, acute care and total costs for 1 year post index date. Results The study included 59,830 propensity-matched individuals. Results indicate that recommended glycemic control, compared to poor glycemic control, was associated with statistically significantly lower all-cause acute care ($23,868 ± $21,776 vs. $24,352 ± $22,223), drug ($10,277 ± $14,671 vs. $10,540 ± $14,928), and total medical costs ($41,381 ± $42,757 vs. $42,054 ± $43,422) but significantly higher outpatient costs ($7290 ± $12,028 vs. $7026 ± $11,587) (all p < 0.0001). Sensitivity analyses examined results based upon alternative HbA1c thresholds of ≤ 6.5% and < 8%. Results were generally robust to alternative HbA1c thresholds, with higher HbA1c thresholds associated with higher all-cause total costs as well as increased savings for having HbA1c below threshold. Conclusions Glycemic control was associated with significantly lower all-cause total, drug, and acute care medical costs. Given the high prevalence of T2D in the USA, our results suggest potential economic benefits associated with glycemic control for healthcare providers.


  • Open Access

    Impact on glycated haemoglobin and body weight changes after stopping tirzepatide for 4 weeks in the SURPASS‐1 monotherapy trial

    by Julio Rosenstock, Clare J. Lee, Laura Fernández Landó, Minzhi Liu, Chrisanthi A. Karanikas, Vivian T. Thieu


  • Open Access

    Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme

    by Sue D. Pedersen, Francesco Giorgino, Guillermo Umpierrez, Vivian T. Thieu, Angel Rodríguez, Claudia Nicolay, Laura Fernández Landó, Chrisanthi A. Karanikas, Jacek Kiljanski

    Aim: To assess the relationship between HbA1c and body weight reductions with tirzepatide treatment (5, 10 or 15 mg). Materials and Methods: HbA1c and body weight data at 40 weeks (SURPASS‐1, ‐2 and ‐5) and 52 weeks (SURPASS‐3 and ‐4) were analysed by trial. Results: Across the SURPASS clinical trials, HbA1c reductions from baseline were observed in 96%‐99%, 98%‐99% and 94%‐99% of participants treated with tirzepatide 5, 10 and 15 mg, respectively. Moreover, 87%‐94%, 88%‐95% and 88%‐97% of participants, respectively, experienced weight loss associated with HbA1c reductions. Statistically significant associations (correlation coefficients ranging from 0.1438 to 0.3130 across studies; P ≤ .038) between HbA1c and body weight changes were observed with tirzepatide in SURPASS‐2, ‐3, ‐4 (all doses) and ‐5 (tirzepatide 5 mg only). Conclusions: In this post hoc analysis, consistent reductions in both HbA1c and body weight were observed in most participants treated with tirzepatide at doses of 5, 10 or 15 mg. A statistically significant but modest association between HbA1c and body weight change was observed in SURPASS‐2, SURPASS‐3 and SURPASS‐4, suggesting that both weight‐independent and weight‐dependent mechanisms are responsible for the tirzepatide‐induced improvement in glycaemic control.